EXEL Quick Quote EXEL - Free Report) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this drug developer would post earnings of $0.07 per share when it actually produced earnings of $0.29, delivering a surprise of 314.29%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $355.98 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.02%. This compares to year-ago revenues of $270.23 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Exelixis shares have added about 5.8% since the beginning of the year versus the S&P 500's decline of -16.3%.
What's Next for Exelixis?
While Exelixis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this
earnings release, the estimate revisions trend for Exelixis: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.21 on $410.57 million in revenues for the coming quarter and $0.89 on $1.69 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Albireo Pharma (
ALBO Quick Quote ALBO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2022. The results are expected to be released on May 16.
This company is expected to post quarterly loss of $2.02 per share in its upcoming report, which represents a year-over-year change of +11.8%. The consensus EPS estimate for the quarter has been revised 20.6% lower over the last 30 days to the current level.
Albireo Pharma's revenues are expected to be $7.82 million, up 296.9% from the year-ago quarter.